How Compression Force and Lubricant Ratio Govern Disintegration in Chlorphenamine Maleate Tablets

Compressed tablets for canine and feline antihistamine therapy use chlorphenamine maleate at a typical addition ratio of 4.0% w/w, equivalent to 4 mg of active in a 100 mg tablet core. The low label claim relative to total core mass makes content uniformity a primary control parameter; bulk powder is prepared in a 600 L twin-shell V-blender with an intensifier bar operated at 12 rpm for 18 minutes. The active phase is first passed through a 40 mesh (425 µm) sieve together with lactose monohydrate in a 1:3 pre-blend before introduction into the main powder bed. Direct compression is maintained over wet granulation to avoid a drying step that can accelerate degradation product formation above the USP Chlorpheniramine Maleate Monograph specified individual impurity limit. Dissolution is tested according to USP <711>, with Q not less than 80% at 30 minutes in 900 mL of 0.1 N hydrochloric acid at 37 °C using paddle apparatus at 50 rpm. Magnesium stearate is limited to 0.5% w/w; addition above 0.75% w/w produces measurable retardation of dissolution in low-porosity cores compressed at 14 kN. Compression is maintained between 8 kN and 14 kN on a rotary tablet press with D tooling; friability must remain below 1.0%, and disintegration is specified at <15 minutes under USP <701>. Industry compliance for this dosage form is anchored to 21 CFR 210 and 21 CFR 211 for veterinary drug product manufacture, with residual solvents controlled under VICH GL18 and impurities under VICH GL11. Terminal finished product types are uncoated or film-coated 4 mg and 8 mg tablets for oral administration to companion animals under veterinary prescription.

Thermal Degradation Control During Steam Sterilization of Chlorphenamine Maleate Injections

Injectable chlorphenamine maleate is processed as a clear aqueous solution at an API addition ratio of 1.0% w/v, corresponding to 10 mg/mL in Water for Injection. The solution is buffered to pH 5.0–6.0 with dilute hydrochloric acid or sodium hydroxide; pH drift above 6.5 accelerates oxidative discoloration during terminal sterilization and shortens shelf-life at 25 °C. Dissolution is performed in a jacketed stainless steel vessel under a nitrogen headspace at 20–25 °C, followed by addition of sodium chloride to 0.86% w/v and adjustment to final volume. The bulk solution is recirculated through a 0.22 µm PVDF membrane filter and filled into amber Type I glass vials. Terminal sterilization uses a validated saturated steam cycle at 121 °C for 15 minutes; the chamber load must be qualified with thermocouples to ensure that all vials reach the designated F₀ of 12 minutes. Sterility is tested according to USP <71> and Ph. Eur. 2.6.1, bacterial endotoxins according to USP <85> and Ph. Eur. 2.6.14, and residual solvents under VICH GL18. Particulate matter in injectable solutions is controlled to USP <788> limits. The terminal product types are 10 mg/mL chlorphenamine maleate injection in amber Type I vials of 20 mL, 50 mL, and 100 mL, used primarily for acute hypersensitivity and urticarial episodes in equine and emergency small-animal practice. Published data for specific process configurations using continuous sterilization of chlorphenamine maleate are limited; batch terminal sterilization remains the standard validation format.

For ophthalmic delivery in equine and canine allergic conjunctivitis, chlorphenamine maleate is formulated as a sterile filtered solution at 2.5 mg/mL, an API addition ratio of 0.25% w/v. This addition ratio balances local antihistamine effect against ocular irritation potential at higher concentrations. Tonicity is adjusted with sodium chloride to 290–300 mOsm/kg, measured by freezing point depression, and pH is fixed at 6.0–6.5 to maintain chlorphenamine maleate solubility while minimizing corneal discomfort. Preservative selection is limited to benzalkonium chloride at 0.01% w/v when multidose dropper bottles are used; single-dose containers are filled without preservative due to the absence of a validated preservative efficacy profile for the target species. The solution is compounded in a closed mixing vessel and sterilized by filtration through a 0.22 µm polyethersulfone membrane under Grade A unidirectional airflow. Fill volume is controlled by peristaltic pump with in-line checkweighing to ±5%. Quality tests include USP <771> for ophthalmic product attributes, USP <789> for particulate matter, USP <71> and Ph. Eur. 2.6.1 for sterility, and Ph. Eur. 2.6.14 for bacterial endotoxins. The terminal finished product types are 2.5 mg/mL ophthalmic solution in 5 mL and 10 mL low-density polyethylene dropper bottles, dispensed under veterinary authorization for non-food-producing equine and companion animal patients.

When Capsule Fill Weight Variability Meets API Potency in a Low-Dose Antihistamine

Capsule filling of chlorphenamine maleate is sensitive to blend segregation because the API addition ratio can be as low as 2.5% w/w in a 2 mg/80 mg fill and 3.3% w/w in a 4 mg/120 mg fill. The low active fraction requires a geometric dilution sequence in which chlorphenamine maleate is first mixed with lactose monohydrate in a 1:1 ratio, then 1:3, then incorporated into the remaining excipient mass. Blending is performed in a 200 L bin blender at 10 rpm for 15 minutes; the blend is passed through a 60 mesh (250 µm) screen before final lubrication with magnesium stearate at 0.5% w/w. Encapsulation is performed on a dosator-type automatic capsule filler with size 3 hard gelatin or hypromellose shells, with fill weight control tolerance of ±5%. In-process blend uniformity requires an RSD of ≤ 5.0% at 10 sampling points; finished capsule content uniformity is tested according to USP <905> and dissolution according to USP <711>. The target dissolution acceptance is Q not less than 80% at 30 minutes in 0.1 N hydrochloric acid. Residual solvents are controlled under VICH GL18; degradation impurities follow VICH GL11. The terminal capsule products are 2 mg and 4 mg chlorphenamine maleate capsules for feline and small equine patients. The following gradient summarizes the low-dose filling window:

For oral powder and granule presentations intended for non-food equine use, the API is dissolved in the binder phase at 5.0 mg/g (0.50% w/w) or 10.0 mg/g (1.00% w/w) in maltodextrin- and lactose-based carriers to avoid dry-powder segregation. The active is first dissolved in a 5% w/v hypromellose binder solution at 30 °C; the solution is sprayed onto the fluidised carrier in a top-spray fluid bed granulator with inlet air temperature 60 °C and product bed temperature maintained at 28–32 °C. Drying continues until moisture content is ≤ 2.0% by loss on drying because residual water above this threshold promotes hydrolysis of the maleate salt and surface stickiness during sachet filling. Granules are passed through an 850 µm sieve and filled into moisture-barrier sachets under RH ≤ 35%. Dissolution of the reconstituted granules, when labelled for solution preparation, follows USP <711> with Q ≥ 80% at 30 minutes; residual solvent levels are bounded by VICH GL18. Compounded powder preparations intended for short-term veterinary use follow USP <795> when prepared in registered veterinary pharmacies. This dosage form is restricted to non-food-producing species because no maximum residue limit for chlorphenamine maleate in edible tissues has been assigned. Terminal product types are 1 g and 2 g oral granulate sachets delivering 5 mg and 10 mg chlorphenamine maleate, respectively, for companion equine and special-species patients.

Prescription Premix Homogeneity for Non-Food-Chain Species at 1.0% w/w

In non-food-chain zoo and companion equine practice, a prescription premix containing chlorphenamine maleate at 10 mg/g (1.0% w/w) is prepared only for species excluded from food production; the absence of an established maximum residue limit excludes food-producing animal application. The carrier system is anhydrous dextrose or maltodextrin with particle size below 850 µm; API is added by geometric dilution in 1:10 steps to control content uniformity. Bulk mixing is performed in a double-cone blender at 65% fill volume and 14 rpm for 20 minutes; the operation is conducted in a room maintained at RH ≤ 40% because chlorphenamine maleate is hygroscopic and the maleate salt softens above this threshold. In-process samples are taken from 10 locations and must achieve an RSD of ≤ 5.0% before discharge. Packaging is immediate in aluminium-lined bags to protect against moisture and light; testing for degradation products follows VICH GL11, and residual solvents are limited by VICH GL18. Manufacturing documentation follows 21 CFR 211 for registered veterinary drug products, while extemporaneous preparation is performed under USP <795>. The terminal product type is a 1.0% w/w chlorphenamine maleate oral premix in 1 kg and 5 kg aluminium-lined bulk containers, dispensed under veterinary authorization for oral administration after dilution into feed or a palatable vehicle.